BioCentury
ARTICLE | Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

March 27, 2020 1:34 AM UTC
Updated on Mar 27, 2020 at 1:42 AM UTC


Access this Article